Literature DB >> 10942235

Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase.

H F Salloukh1, P Laneuville.   

Abstract

The acquisition of the Philadelphia (Ph) chromosome (or BCR-ABL translocation) represents a detrimental pathophysiological event in humans. The activated tyrosine kinases, which are produced by this translocation, are associated with fatal hematological malignancies. The initial molecular dissection of BCR-ABL has linked the expression of this constitutively activated kinase with enhanced genomic instability. We directly evaluated the consequence of BCR-ABL expression on genomic instability using the Big Blue in vivo mutagenesis mouse system. We report that the expression of BCR-ABL in both spleens and kidneys confers a mutator phenotype represented by a statistically significant elevation in mutant frequencies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942235     DOI: 10.1038/sj.leu.2401855

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  11 in total

1.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

2.  BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells.

Authors:  Artur Slupianek; Michal O Nowicki; Mateusz Koptyra; Tomasz Skorski
Journal:  DNA Repair (Amst)       Date:  2005-11-16

Review 3.  BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.

Authors:  B A Burke; M Carroll
Journal:  Leukemia       Date:  2010-05-06       Impact factor: 11.528

4.  aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL.

Authors:  Jeremy D Bartos; Daniel P Gaile; Devin E McQuaid; Jeffrey M Conroy; Huferesh Darbary; Norma J Nowak; Annemarie Block; Nicholas J Petrelli; Arnold Mittelman; Daniel L Stoler; Garth R Anderson
Journal:  Mutat Res       Date:  2007-01-02       Impact factor: 2.433

Review 5.  Mechanisms of transformation by the BCR/ABL oncogene.

Authors:  M Sattler; J D Griffin
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

6.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Authors:  Mateusz Koptyra; Rafal Falinski; Michal O Nowicki; Tomasz Stoklosa; Ireneusz Majsterek; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

7.  Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.

Authors:  Hardik Modi; Tinisha McDonald; Su Chu; Jiing-Kuan Yee; Stephen J Forman; Ravi Bhatia
Journal:  Blood       Date:  2007-03-08       Impact factor: 22.113

8.  Recommendations of the canadian consensus group on the management of chronic myeloid leukemia.

Authors:  P Laneuville; M J Barnett; R Bélanger; S Couban; D L Forrest; D C Roy; J H Lipton
Journal:  Curr Oncol       Date:  2006-12       Impact factor: 3.677

9.  Deletion 9p23 to 9p11.1 as sole additional abnormality in a Philadelphia positive chronic myeloid leukemia in blast crisis: a rare event.

Authors:  Abdulsamad Wafa; Manar Asa'ad; Adnan Ikhtiar; Thomas Liehr; Walid Al-Achkar
Journal:  Mol Cytogenet       Date:  2015-08-04       Impact factor: 2.009

Review 10.  DNA Repair--A Double-Edged Sword in the Genomic Stability of Cancer Cells--The Case of Chronic Myeloid Leukemia.

Authors:  Elzbieta Pawlowska; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.